NTLA Overview
Upcoming Projects (NTLA)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (NTLA)
-
A Second Look: Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Tickers: NTLA, ALNY
Executed On: Dec 19, 2024 at 12:00 PM EST -
Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Tickers: NTLA, ALNY
Executed On: Dec 06, 2024 at 04:00 PM EST -
A Third Look: Discussing the positive results from the Phase 2 Study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for HAE
Ticker: NTLA
Executed On: Dec 05, 2024 at 05:00 PM EST -
A Second View: Digging into the data presented at AHA 2024 on nexiguran ziclumeran and Nucresiran in patients with ATTR-CM
Tickers: NTLA, ALNY
Executed On: Dec 05, 2024 at 03:30 PM EST -
A Second Look: Discussing the positive results from the Phase 2 Study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for HAE
Ticker: NTLA
Executed On: Nov 04, 2024 at 04:00 PM EST -
Discussing the positive results from the Phase 2 Study of NTLA-2002, an investigational in vivo CRISPR gene editing treatment for HAE
Ticker: NTLA
Executed On: Oct 31, 2024 at 03:15 PM EDT -
A Third Look: Discussing results from the Phase 2, randomized, double-blind, placebo-controlled study of NTLA-2002 in patients with HAE
Ticker: NTLA
Executed On: Sep 30, 2024 at 09:00 AM EDT -
A Second Look: Discussing results from the Phase 2, randomized, double-blind, placebo-controlled study of NTLA-2002 in patients with HAE
Ticker: NTLA
Executed On: Sep 04, 2024 at 11:00 AM EDT -
Discussing results from the Phase 2, randomized, double-blind, placebo-controlled study of NTLA-2002 in patients with HAE
Ticker: NTLA
Executed On: Aug 22, 2024 at 12:00 PM EDT -
A Second View: Looking at the data for redosing NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in patients with transthyretin (ATTR) amyloidosis
Ticker: NTLA
Executed On: Jul 10, 2024 at 11:00 AM EDT -
Looking at the data for redosing NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in patients with transthyretin (ATTR) amyloidosis
Ticker: NTLA
Executed On: Jul 09, 2024 at 10:30 AM EDT -
A Third View: Looking into the phase 1 data on Intellia Therapeutics' NTLA-2002 in patients with hereditary angioedema.
Ticker: NTLA
Executed On: Jun 26, 2023 at 04:00 PM EDT -
A Second View: Looking into the phase 1 data on Intellia Therapeutics' NTLA-2002 in patients with hereditary angioedema.
Ticker: NTLA
Executed On: Jun 23, 2023 at 09:00 AM EDT -
Looking into the phase 1 data on Intellia Therapeutics' NTLA-2002 in patients with hereditary angioedema.
Ticker: NTLA
Executed On: Jun 23, 2023 at 08:00 AM EDT -
A third discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 03:00 PM EDT -
A second discussion of the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 23, 2022 at 02:00 PM EDT -
A look at the potential of Intella's CRSPR-Cas9 based gene editing program (NTLA-2001) to treat patients with transthyretin-mediated amyloid polyneuropathy
Ticker: NTLA
Executed On: Sep 23, 2022 at 01:00 PM EDT -
Discussing the clinical landscape of Hereditary Angioedema, with a focus on the phase 1/2 results of Intellia's CRISPR treatment, NTLA-2002
Tickers: NTLA, BCRX, IONS, TAK
Executed On: Sep 22, 2022 at 12:00 PM EDT
Upcoming & Overdue Catalysts (NTLA)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (NTLA)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
